Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3428)
All Articles published online
|
Jun 28, 2008 (publication date) through Nov 30, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Schulze-Bergkamen H, Ehrenberg R, Hickmann L, Vick B, Urbanik T, Schimanski CC, Berger MR, Schad A, Weber A, Heeger S, Galle PR, Moehler M. Bcl-xL and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. World J Gastroenterol 2008; 14(24): 3829-3840 [PMID: 18609706 DOI: 10.3748/wjg.14.3829] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i24/3829.htm |
| Number | Citing Articles |
| 1 |
Bruno Christian Koehler, Toni Urbanik, Binje Vick, Regina Johanna Boger, Steffen Heeger, Peter R Galle, Marcus Schuchmann, Henning Schulze-Bergkamen. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World Journal of Gastroenterology 2009; 15(47): 5924-5935 doi: 10.3748/wjg.15.5924
|
| 2 |
Seon Min Woo, Kyoung-jin Min, Bo Ram Seo, Taeg Kyu Kwon. YM155 sensitizes TRAIL-induced apoptosis through cathepsin S-dependent down-regulation of Mcl-1 and NF-κB-mediated down-regulation of c-FLIP expression in human renal carcinoma Caki cells. Oncotarget 2016; 7(38): 61520 doi: 10.18632/oncotarget.11137
|
| 3 |
D Schmid, G E Jarvis, F Fay, D M Small, M K Greene, J Majkut, S Spence, K M McLaughlin, K D McCloskey, P G Johnston, A Kissenpfennig, D B Longley, C J Scott. Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity. Cell Death & Disease 2014; 5(10): e1454 doi: 10.1038/cddis.2014.413
|
| 4 |
G Polier, J Ding, B V Konkimalla, D Eick, N Ribeiro, R Köhler, M Giaisi, T Efferth, L Desaubry, P H Krammer, M Li-Weber. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death & Disease 2011; 2(7): e182 doi: 10.1038/cddis.2011.66
|
| 5 |
Haeng‐Eun Lee, Jeong‐Seok Nam, Ji‐Ae Shin, In‐Sun Hong, In‐Hyoung Yang, Myung‐Jo You, Sung‐Dae Cho. Convallaria keiskei as a novel therapeutic alternative for salivary gland cancer treatment by targeting myeloid cell leukemia‐1. Head & Neck 2016; 38(S1) doi: 10.1002/hed.24096
|
| 6 |
Soyoung Choi, Zhengming Chen, Laura H. Tang, Yuanzhang Fang, Sandra J. Shin, Nicole C. Panarelli, Yao-Tseng Chen, Yi Li, Xuejun Jiang, Yi-Chieh Nancy Du. Bcl-xL promotes metastasis independent of its anti-apoptotic activity. Nature Communications 2016; 7(1) doi: 10.1038/ncomms10384
|
| 7 |
Bodvael Pennarun, Jan H Kleibeuker, Wytske Boersma‐ van Ek, Frank AE Kruyt, Harry Hollema, Elisabeth GE de Vries, Steven de Jong. Targeting FLIP and Mcl‐1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL. The Journal of Pathology 2013; 229(3): 410 doi: 10.1002/path.4138
|
| 8 |
Alena Vaculová, Jiřina Hofmanová, Jiřina Zatloukalová, Alois Kozubík. Differences in TRAIL-induced changes of Mcl-1 expression among distinct human colon epithelial cell lines. Experimental Cell Research 2009; 315(19): 3259 doi: 10.1016/j.yexcr.2009.09.019
|
| 9 |
Xiang Guoan, Wang Hanning, Chen Kaiyun, Liu Hao. Adenovirus-mediated siRNA targeting Mcl-1 gene increases radiosensitivity of pancreatic carcinoma cells in vitro and in vivo. Surgery 2010; 147(4): 553 doi: 10.1016/j.surg.2009.10.033
|
| 10 |
Amirmohammad Nasiri Kenari, Kenneth Kastaniegaard, David W. Greening, Mitch Shambrook, Allan Stensballe, Lesley Cheng, Andrew F. Hill. Proteomic and Post‐Translational Modification Profiling of Exosome‐Mimetic Nanovesicles Compared to Exosomes. PROTEOMICS 2019; 19(8) doi: 10.1002/pmic.201800161
|
| 11 |
Ulrich-Axel Bommer, Kara L. Vine, Prianka Puri, Martin Engel, Lisa Belfiore, Karen Fildes, Marijka Batterham, Alistair Lochhead, Morteza Aghmesheh. Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin. Cell Communication and Signaling 2017; 15(1) doi: 10.1186/s12964-017-0164-3
|
| 12 |
T Trarbach, M Moehler, V Heinemann, C-H Köhne, M Przyborek, C Schulz, V Sneller, G Gallant, S Kanzler. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. British Journal of Cancer 2010; 102(3): 506 doi: 10.1038/sj.bjc.6605507
|
| 13 |
Bruno Christian Koehler, Anna-Lena Scherr, Stephan Lorenz, Toni Urbanik, Nicole Kautz, Christin Elssner, Stefan Welte, Justo Lorenzo Bermejo, Dirk Jäger, Henning Schulze-Bergkamen, Jun Li. Beyond Cell Death – Antiapoptotic Bcl-2 Proteins Regulate Migration and Invasion of Colorectal Cancer Cells In Vitro. PLoS ONE 2013; 8(10): e76446 doi: 10.1371/journal.pone.0076446
|
| 14 |
Zineb El Fajoui, Florent Toscano, Guillaume Jacquemin, Jacques Abello, Jean–Yves Scoazec, Olivier Micheau, Jean–Christophe Saurin. Oxaliplatin Sensitizes Human Colon Cancer Cells to TRAIL Through JNK-Dependent Phosphorylation of Bcl-xL. Gastroenterology 2011; 141(2): 663 doi: 10.1053/j.gastro.2011.04.055
|
| 15 |
Wei Sun, Yang Ge, Junpeng Cui, Yifan Yu, Baolin Liu. Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2. Molecular Therapy - Oncolytics 2021; 21: 87 doi: 10.1016/j.omto.2021.03.010
|
| 16 |
Janica C. Wong, Madhavi Bathina, Ronald R. Fiscus. Cyclic GMP/protein kinase G type‐Iα (PKG‐Iα) signaling pathway promotes CREB phosphorylation and maintains higher c‐IAP1, livin, survivin, and Mcl‐1 expression and the inhibition of PKG‐Iα kinase activity synergizes with cisplatin in non‐small cell lung cancer cells. Journal of Cellular Biochemistry 2012; 113(11): 3587 doi: 10.1002/jcb.24237
|
| 17 |
Bruno Christian Koehler, Anna-Lena Scherr, Stephan Lorenz, Christin Elssner, Nicole Kautz, Stefan Welte, Dirk Jaeger, Toni Urbanik, Henning Schulze-Bergkamen, Andrei L. Gartel. Pan-Bcl-2 Inhibitor Obatoclax Delays Cell Cycle Progression and Blocks Migration of Colorectal Cancer Cells. PLoS ONE 2014; 9(9): e106571 doi: 10.1371/journal.pone.0106571
|
| 18 |
E P Booy, E S Henson, S B Gibson. Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer. Oncogene 2011; 30(20): 2367 doi: 10.1038/onc.2010.616
|
| 19 |
Diego Y. Grinman, Leonardo Romorini, Diego M. Presman, Luciana Rocha-Viegas, Omar A. Coso, Carlos Davio, Adali Pecci. Role of 3′-5′-cyclic adenosine monophosphate on the epidermal growth factor dependent survival in mammary epithelial cells. Molecular and Cellular Endocrinology 2016; 419: 259 doi: 10.1016/j.mce.2015.10.026
|
| 20 |
Rita Sala, Elisa Rioja-Blanco, Naroa Serna, Laura Sánchez-García, Patricia Álamo, Lorena Alba-Castellón, Isolda Casanova, Antonio López-Pousa, Ugutz Unzueta, María Virtudes Céspedes, Esther Vázquez, Antonio Villaverde, Ramon Mangues. GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases. Drug Delivery 2022; 29(1): 1384 doi: 10.1080/10717544.2022.2069302
|
| 21 |
Anthony W. Tolcher, Patricia LoRusso, Jennifer Arzt, Todd A. Busman, Guinan Lian, Niki S. Rudersdorf, Carol Ann Vanderwal, Jeffrey F. Waring, Jianning Yang, Kyle D. Holen, Lee S. Rosen. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study. Cancer Chemotherapy and Pharmacology 2015; 76(5): 1041 doi: 10.1007/s00280-015-2882-9
|
| 22 |
Jorn Markus Schattenberg, Marcus Schuchmann, Peter Robert Galle. Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. Journal of Gastroenterology and Hepatology 2011; 26(s1): 213 doi: 10.1111/j.1440-1746.2010.06582.x
|
| 23 |
Wang Likui, Liu Qun, Zhou Wanqing, Shao Haifeng, Li Fangqiu, Li Xiaojun. Prognostic role of myeloid cell leukemia‐1 protein (Mcl‐1) expression in human gastric cancer. Journal of Surgical Oncology 2009; 100(5): 396 doi: 10.1002/jso.21344
|
| 24 |
Ting Zhang, Chun Zhao, Liang Luo, Hua Zhao, Jing Cheng, Fei Xu. The expression of Mcl-1 in human cervical cancer and its clinical significance. Medical Oncology 2012; 29(3): 1985 doi: 10.1007/s12032-011-0005-y
|
| 25 |
B. N. Polite, B. E. Sylvester, O. I. Olopade. Race and Subset Analyses in Clinical Trials: Time to Get Serious About Data Integration. JNCI Journal of the National Cancer Institute 2011; 103(20): 1486 doi: 10.1093/jnci/djr382
|
| 26 |
Chi-Hung Or, Yachu Chang, Wei-Cheng Lin, Wee-Chyan Lee, Hong-Lin Su, Muk-Wing Cheung, Chang-Po Huang, Cheesang Ho, Chia-Che Chang. Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells. International Journal of Molecular Sciences 2016; 18(1): 44 doi: 10.3390/ijms18010044
|
| 27 |
Abid R. Mattoo, Jingyu Zhang, Luis A. Espinoza, J. Milburn Jessup. Inhibition of NANOG/NANOGP8 Downregulates MCL-1 in Colorectal Cancer Cells and Enhances the Therapeutic Efficacy of BH3 Mimetics. Clinical Cancer Research 2014; 20(21): 5446 doi: 10.1158/1078-0432.CCR-14-1134
|
| 28 |
Estrella Mariel Levy, Gabriela Sycz, Juan Martin Arriaga, María Marcela Barrio, Erika María von Euw, Sergio Bayo Morales, Mariana González, José Mordoh, Michele Bianchini. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. Innate Immunity 2009; 15(2): 91 doi: 10.1177/1753425908101404
|